501 related articles for article (PubMed ID: 24574235)
1. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis.
Aggarwal R; Bandos A; Reed AM; Ascherman DP; Barohn RJ; Feldman BM; Miller FW; Rider LG; Harris-Love MO; Levesque MC; ; Oddis CV
Arthritis Rheumatol; 2014 Mar; 66(3):740-9. PubMed ID: 24574235
[TBL] [Abstract][Full Text] [Related]
2. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.
Oddis CV; Reed AM; Aggarwal R; Rider LG; Ascherman DP; Levesque MC; Barohn RJ; Feldman BM; Harris-Love MO; Koontz DC; Fertig N; Kelley SS; Pryber SL; Miller FW; Rockette HE;
Arthritis Rheum; 2013 Feb; 65(2):314-24. PubMed ID: 23124935
[TBL] [Abstract][Full Text] [Related]
3. Biologic predictors of clinical improvement in rituximab-treated refractory myositis.
Reed AM; Crowson CS; Hein M; de Padilla CL; Olazagasti JM; Aggarwal R; Ascherman DP; Levesque MC; Oddis CV;
BMC Musculoskelet Disord; 2015 Sep; 16():257. PubMed ID: 26382217
[TBL] [Abstract][Full Text] [Related]
4. Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab.
Aggarwal R; Oddis CV; Goudeau D; Koontz D; Qi Z; Reed AM; Ascherman DP; Levesque MC
Rheumatology (Oxford); 2016 Jun; 55(6):991-9. PubMed ID: 26888854
[TBL] [Abstract][Full Text] [Related]
5. Association of various myositis-specific autoantibodies with dermatomyositis and polymyositis triggered by pregnancy.
Akiyama C; Shirai T; Sato H; Fujii H; Ishii T; Harigae H
Rheumatol Int; 2022 Jul; 42(7):1271-1280. PubMed ID: 33837447
[TBL] [Abstract][Full Text] [Related]
6. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.
Ceribelli A; Isailovic N; De Santis M; Generali E; Fredi M; Cavazzana I; Franceschini F; Cantarini L; Satoh M; Selmi C
Clin Rheumatol; 2017 Feb; 36(2):469-475. PubMed ID: 27761751
[TBL] [Abstract][Full Text] [Related]
7. Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis.
Cruellas MG; Viana Vdos S; Levy-Neto M; Souza FH; Shinjo SK
Clinics (Sao Paulo); 2013 Jul; 68(7):909-14. PubMed ID: 23917652
[TBL] [Abstract][Full Text] [Related]
8. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients.
Cooper MA; Willingham DL; Brown DE; French AR; Shih FF; White AJ
Arthritis Rheum; 2007 Sep; 56(9):3107-11. PubMed ID: 17763414
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in the treatment of inflammatory myopathies: a review.
Fasano S; Gordon P; Hajji R; Loyo E; Isenberg DA
Rheumatology (Oxford); 2017 Jan; 56(1):26-36. PubMed ID: 27121778
[TBL] [Abstract][Full Text] [Related]
10. Muscle Biopsy Findings in Combination With Myositis-Specific Autoantibodies Aid Prediction of Outcomes in Juvenile Dermatomyositis.
Deakin CT; Yasin SA; Simou S; Arnold KA; Tansley SL; Betteridge ZE; McHugh NJ; Varsani H; Holton JL; Jacques TS; Pilkington CA; Nistala K; Wedderburn LR;
Arthritis Rheumatol; 2016 Nov; 68(11):2806-2816. PubMed ID: 27214289
[TBL] [Abstract][Full Text] [Related]
11. Therapy of polymyositis and dermatomyositis.
Marie I; Mouthon L
Autoimmun Rev; 2011 Nov; 11(1):6-13. PubMed ID: 21740984
[TBL] [Abstract][Full Text] [Related]
12. The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies.
Li S; Ge Y; Yang H; Wang T; Zheng X; Peng Q; Lu X; Wang G
Clin Rheumatol; 2019 Aug; 38(8):2171-2179. PubMed ID: 30863950
[TBL] [Abstract][Full Text] [Related]
13. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population.
Unger L; Kampf S; Lüthke K; Aringer M
Rheumatology (Oxford); 2014 Sep; 53(9):1630-8. PubMed ID: 24706995
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
[TBL] [Abstract][Full Text] [Related]
15. Dermatomyositis and polymyositis: new treatment targets on the horizon.
Hak AE; de Paepe B; de Bleecker JL; Tak PP; de Visser M
Neth J Med; 2011 Oct; 69(10):410-21. PubMed ID: 22058260
[TBL] [Abstract][Full Text] [Related]
16. Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis.
Shah M; Targoff IN; Rice MM; Miller FW; Rider LG;
Arthritis Rheum; 2013 Jul; 65(7):1934-41. PubMed ID: 23658122
[TBL] [Abstract][Full Text] [Related]
17. Humoral immunity in polymyositis/dermatomyositis.
Targoff IN
J Invest Dermatol; 1993 Jan; 100(1):116S-123S. PubMed ID: 8423380
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of specific autoantibodies in juvenile dermatomyositis.
Feldman BM; Reichlin M; Laxer RM; Targoff IN; Stein LD; Silverman ED
J Rheumatol; 1996 Oct; 23(10):1794-7. PubMed ID: 8895161
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of rituximab in dermatomyositis and polymyositis refractory to conventional therapy.
Sánchez-Fernández SÁ; Carrasco Fernández JA; Rojas Vargas LM
Reumatol Clin; 2013; 9(2):117-9. PubMed ID: 22771272
[TBL] [Abstract][Full Text] [Related]
20. Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial.
Rider LG; Yip AL; Horkayne-Szakaly I; Volochayev R; Shrader JA; Turner ML; Kong HH; Jain MS; Jansen AV; Oddis CV; Fleisher TA; Miller FW
Clin Exp Rheumatol; 2014; 32(5):689-96. PubMed ID: 25068290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
